What Is SPRAVATO™?
A GROUNDBREAKING TREATMENT FOR DEPRESSION
Spravato (Esketamine) is a nasal spray medication that is used as an adjunct to an oral antidepressant in adults with treatment-resistant depression. It is a form of ketamine, an anesthetic that has been used in medical settings for decades. Spravato works by binding to a specific receptor in the brain, the N-methyl-D-aspartate (NMDA) receptor, which helps to regulate the level of certain neurotransmitters, such as glutamate and dopamine, that are involved in mood regulation.
Spravato for Treatment-Resistant Depression
Depression is not as simple as just “sadness.” Sadness is a feeling that comes and goes with everyday life. Almost 300 million people suffer from depression worldwide, and despite a variety of depression treatments available, many continue to suffer without relief from these medications.
Fortunately, SPRAVATO™ – the breakthrough FDA-approved esketamine nasal spray – is showing excellent results in relieving those symptoms of depression. As a SPRAVATO™ REMS-certified treatment provider, our treatment team can alleviate even the most severe forms of treatment-resistant depression.
How Is SPRAVATO™ Different?
Rising depression rates worldwide make one thing clear: the current antidepressants so commonly prescribed are not bringing adequate relief to all those suffering.
These oral antidepressants typically aim to treat depression by increasing certain neurotransmitters in the brain to affect mood. SPRAVATO™ works differently – it targets the NMDA receptor antagonist and may be able to reset and restore neuronal connections. Through this, SPRAVATO™ can treat the disorder, not just the symptoms.